Digital PCR-Based Method for Detecting CDKN2A Loss in Brain Tumours.
Shlomo TsurielVictoria HannesAsala HasonaMichal RazDov HershkovitzPublished in: Molecular diagnosis & therapy (2022)
The method presented can give a fast, cost-effective, clinically reliable evaluation of CDKN2A loss in tissue with more than 50% tumour content. Its ability to work with old samples and with low amounts of DNA makes it the favoured assay in cases where other techniques fail.